SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA).
“This trial establishes the feasibility of adjuvant treatment in EHCC and GBCA and provides critically needed prospective data acquired in a multi-institutional setting. Both efficacy data and completion rate are promising and warrant further investigation in a phase 3 trial. Clinical trial information: NCT00789958.”
http://abstracts.asco.org/144/AbstView_144_132530.html